In 2014, the Transfusion Requirements in Septic Shock (TRISS trial), showed similar outcomes with no 90-day mortality differences for lower (Hb < 7.0 g/dL) or higher (Hb < 9.0 g/dL) haemoglobin thresholds for transfusion in septic shock patients [14]. This evidence concerns the gene GSTM1 and Shock.